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Abstract
The family of cationic lipid transfection reagents described here demonstrates a modular design that offers potential for the
ready synthesis of a wide variety of molecular variants. The key feature of these new molecules is the use of Tris as a linker
for joining the hydrophobic domain to a cationic head group. The molecular design offers the opportunity to conveniently
synthesise compounds differing in charge, the number and nature of hydrophobic groups in the hydrophobic domain and the
characteristics of the spacer between the cationic and hydrophobic moieties. We show that prototype reagents of this design
can deliver reporter genes into cultured cells with efficiencies rivalling those of established cationic lipid transfection reagents.
A feature of these reagents is that they are not dependent on formulation with a neutral lipid for activity. ß 1999 Elsevier
Science B.V. All rights reserved.
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1. Introduction
It is well established that cationic lipids can be
used to successfully deliver genes and oligonucleo-
tides into a wide variety of di¡erent cell types in
vitro. More recently they have been used for the
delivery of therapeutic genes in a number of gene
therapy clinical trials.
Although less e⁄cient than viruses at delivering a
nucleic acid load into cells, cationic lipids are £exible
delivery agents facilitating the transfer of anything
from oligonucleotides to large gene expression cas-
settes into cells and tissues without raising an im-
mune response or risking oncogenicity resulting
from the inadvertent formation of recombinant virus.
Thus despite the drawbacks, the bene¢ts of cationic
lipid systems have justi¢ed widespread research being
carried out on these compounds as viable alternatives
to viral delivery (for reviews see [1^8]).
In this paper we describe a new class of cationic
lipids which o¡ers a chemical versatility not available
in other compounds of this type. These compounds
take advantage of the observation that the amino
group of the common bu¡er molecule Tris can,
under certain conditions, be induced to form an
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benzyloxy-lysine; Cbz-A-OMe, carbobenzyloxy-alanine methyl
ester; DCM, dichloromethane; DCCD, dicyclohexylcarbodi-
imide; DCU, dicyclohexylurea; DIEA, diisopropylethylamine;
DMAP, dimethylaminopyridine; DMF, dimethylformamide;
DMSO, dimethylsulphoxide; DSC, disuccinimidylcarbonate;
HOSu, N-hydroxysuccinimide; Pd/C, palladium/carbon; K, ly-
sine; P, palmitoyl (hexadecanoyl) ; TBA, tert-butanol; TFA, tri-
£uoroacetic acid; T, Tris(hydroxymethyl)aminomethane; THF,
tetrahydrofuran
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amide linkage with the K-carboxyl group of an ami-
no acid or peptide [9]. These conjugated cationic
molecules have a number of features in common
with classical lipidic molecules used for transfection.
That is, they are characterised by a polar cationic
head group attached to a number of long chain fatty
acyl groups.
We demonstrate that by attaching a cationic pep-
tide to the amino group of Tris and by forming ester
linkages with the long chain fatty acyl molecule
palmitoyl to the hydroxyls of the Tris linker, proto-
type cationic lipopeptides can be formed that e⁄-
ciently deliver DNA containing a L-galactosidase
reporter gene cassette into cells in culture. Further
we demonstrate that varying the number of pal-
mitoyl groups in the hydrophobic domain dramati-
cally alters the transfection activity of these com-
pounds. Transfection activity was not dependent on
formulation with a neutral lipid which signi¢cantly
simpli¢es their preparation and use as transfection
reagents.
2. Materials and methods
2.1. Preparation of cationic lipids
2.1.1. Chemicals and solvents
Boc(K-Cbz) was purchased from Peptide Institute
(Osaka, Japan) and DSC was purchased from Tokyo
Kasei Kogyo (Tokyo, Japan). All the amino acids
were in L-con¢guration and were purchased from
Sigma (St. Louis, MO, USA) unless otherwise noted.
All solvents were of analytical grade and were used
as purchased.
2.1.2. Thin layer chromatography (TLC)
TLC was performed on Alufolein Silica gel 60 F254
plates (Merck) in the following solvent systems: R1f ,
chloroform/methanol/acetic acid: 95:5:3; R2f , chloro-
form/methanol/triethylamine: 95:7:3. Compounds
with UV absorbance were visualised under UV light
and then were sprayed with phosphomolybdic acid
(4% ethanol solution) followed by heating at 120‡C.
Compounds containing unprotected amine groups
were visualised by ninhydrin spray followed by heat-
ing at 120‡C.
2.1.3. High performance liquid chromatography
(HPLC)
Analytical HPLC was carried out on Millipore
Waters HPLC equipment (Waters Chromatography
Division of Millipore, Milford, MA, USA), compris-
ing a 6000A series solvent delivery system with an
automated gradient controller and Model 746 Data
Module. The chromatography was carried out with a
Novapak C18 reverse phase column (100U8 mm).
The peptides and peptide-Tris conjugates were ana-
lysed on a linear gradient elution from 24 to 80%
acetonitrile with 0.1% TFA within 5 min at a £ow
rate of 2 ml/min (System A; RAt ) Detection was car-
ried out at 260 nm using a Waters Lambda Max 480
LC spectrophotometer.
The lipopeptide conjugates were analysed on a C18
column with a linear gradient from 40% water, 50%
acetonitrile and 10% THF to 50% acetonitrile, 50%
THF with 0.1% TFA within 5 min at a £ow rate of
2 ml/min (System B; RBt ).
2.1.4. Preparative HPLC
Separations were carried out on a Millipore
Waters DeltaPrep 4000 HPLC using a PrePak C18
reverse phase column (100U40 mm) eluted with a
linear gradient with the same eluent bu¡er systems
as described above for the analytical HPLC (without
TFA) at a £ow rate of 20 ml/min.
Preparative silica column £ash chromatography
was performed on silica 230^400 mesh ASTM
(Merck).
2.1.5. Nuclear magnetic resonance (NMR)
1H NMR spectra were recorded with a 200 MHz
Brucker spectrophotometer at the probe temperature
of 298 K.
2.2. Compound syntheses
2.2.1. K-Boc(O-Cbz)-lysyl-(O-Cbz)-lysine
[Boc(K-Cbz)2OH]; compound I
Boc(K-Cbz), (2.85 g, 7.5 mmol) was dissolved in
40 ml acetonitrile. HOSu (1 g, 8.7 mmol) was added
to the solution and it was cooled to 0‡C. DCCD
(1.55 g, 7.5 mmol) dissolved in 10 ml acetonitrile
was added dropwise into the reaction mixture. The
solution was stirred at 0‡C for 1 h, transferred to
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room temperature, then stirred a further 3 h to pro-
duce the hydroxysuccinimide ester in 93% yield by
HPLC. DCU precipitate was removed by ¢ltration.
To the ¢ltrate was added 20 ml of 50:50 (v/v) water/
acetonitrile containing 2.1 g (7.5 mmol) K-amino (K-
Cbz) and 1.7 ml DIEA (10 mmol). The reaction mix-
ture was stirred at room temperature overnight. Sol-
vent was removed under reduced pressure and the
resulting oily residue was dissolved in ethyl acetate
and washed with acid, base and water. The ethyl
acetate phase was dried over sodium sulphate and
evaporated to dryness. The residue was triturated
with diethyl ether to obtain 4.5 g of compound I in
93% yield, R1f : 0.52, R
A
t : 7.53 min;
1H NMR: N
(DMSO-d6, ppm), 1.39 (9H, s, Boc(CH3)3), 1.4^1.8
(12H, brs, L, Q, N CH2), 2.99 (4H, brs, O-CH2), 3.95
(1H, m, K-CH), 4.14 (1H, m, K-CH), 5.03 (4H, s, Ar-
CH2), 6.89 (1H, d, K-urethane NH, J = 7.5 Hz), 7.25
(2H, t, O-urethane NH), 7.41 (10H, m, Ar(H)), 7.95
(1H, d, amide NH, J = 8.5 Hz).
2.2.2. K-Amino(O-Cbz)-lysyl-(O-Cbz)-lysine
(TFA3.K-NH3 (K-Cbz)2OH); compound II
Compound I (3.8 g, 5.85 mmol) was dissolved in
10 ml DCM, and cooled to 0‡C. TFA (10 ml) was
added and the reaction mixture stirred at 0‡C for 10
min. After stirring for a further 50 min at room
temperature the solvent and the excess TFA were
removed by evaporation and the oily residue tritu-
rated with diethyl ether yielding 3.9 g of compound
II; R2f : 0.19, R
A
t : 5.78 min.
2.2.3. K-Boc(O-Cbz)-lysyl-(O-Cbz)-lysyl-(O-Cbz)-
lysine [Boc(K-Cbz)3OH]; compound III
Boc(K-Cbz) (2.23 g, 5.85 mmol) was activated by
HOSu and DCCD as described above. DCU was
removed by ¢ltration and the ¢ltrate added to 3.9 g
of compound II. DIEA (2 ml, 11.7 mmol) was added
to the reaction mixture which was then stirred over-
night at room temperature. The solvent was evapo-
rated and the residue dissolved in ethyl acetate and
washed with acid, base and water. The ethyl acetate
solution was dried over sodium sulphate. By concen-
trating the ethyl acetate solution white crystals were
formed which were collected by ¢ltration and dried
to give 3 g of pure compound III as determined by
HPLC. The ¢ltrate was evaporated to dryness and
the residue puri¢ed on the preparative HPLC C18
column to give a further 0.7 g of pure compound
III (total yield: 87%), R1f : 0.36, R
A
t : 7.92 min;
1H
NMR: N (DMSO-d6, ppm), 1.39 (9H, s, Boc(CH3)3),
1.4^1.8 (18H, brs, L, Q, N CH2), 2.99 (6H, brs, O-
CH2), 3.95 (1H, m, K-CH), 4.14 (1H, m, K-CH),
4.34 (1H, m, K-CH), 5.03 (6H, s, Ar-CH2), 6.8
(1H, d, K-urethane NH, J = 7.5 Hz), 7.25 (3H, t, O-
urethane NH), 7.41 (15H, m, Ar(H)), 7.80 (1H, d,
amide NH, J = 8 Hz), 8.15 (1H, d, amide NH, J = 8
Hz).
2.2.4. N-(Cbz-Alanyl)
Tris(hydroxymethyl)aminomethane
(Cbz-AT); compound IV
Cbz-alanine methyl ester (9 g, 0.038 mole) was
dissolved in 100 ml of DMF and Tris (36.5 g, 0.3
mole) in 300 ml of H2O and 350 ml of DMF were
added to the reaction mixture and incubated at 60‡C
for 72 h. The solvents were removed under reduced
pressure and the oily residue redissolved in ethyl ace-
tate and washed with water. The ethyl acetate phase
was dried over anhydrous sodium sulphate and
evaporated to dryness to obtain 4 g of pure com-
pound IV. Subsequent extraction of the water phase
with ethyl acetate yielded a further 2.8 g of the pure
compound representing a total yield of 55%. RAt :
3.96 min; 1H NMR: N (DMSO-d6, ppm), 1.2 (3H,
d, alanine(CH3), J = 6 Hz), 3.63(6H, d, Tris(CH2),
J = 4 Hz), 4.14(1H, m, K-CH), 5.03 (2H, s, Ar-
CH2), 7.15 (1H, s, amide-NH), 7.41 (5H, m,
Ar(H)), 7.5 (1H, d, urethane NH, J = 7.5 Hz).
2.2.5. N-(Alanyl) Tris(hydroxymethyl)aminomethane
(AT); compound V
Compound IV (4 g, 0.012 mole) was dissolved in
60 ml of mixed solvent of DCM/methanol (50:50),
then hydrogenated overnight at 40 psi in a Parr Hy-
drogenator using 10% Pd/C. Pd/C was removed by
¢ltration and the solvents evaporated under reduced
pressure to give 2.2 g of compound V in 94% yield.
The removal of the Cbz group was con¢rmed by 1H
NMR spectroscopy (by disappearance of chemical
shifts at 5.03 and 7.41 ppm).
2.2.6. N-{K-Boc[(O-Cbz) Lysyl]3-alanyl}-
Tris(hydroxymethyl)aminomethane
[Boc(K-Cbz)3-AT]; compound VI
Compound III (1 g, 1.2 mmol) was dissolved in
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40 ml DMF and DSC (0.92 g, 3.6 mmol) added.
After adding DIEA (0.2 ml, 1.2 mmol) and stirring
at room temperature for 1 h the activated ester of
compound III formed with a 78% yield as deter-
mined by HPLC. Compound V (0.46 g, 2.4 mmol)
was added to the reaction mixture and the pH ad-
justed to 8 by adding 0.6 ml of DIEA. The formation
of the title compound was followed by HPLC. After
2 h the activated ester was almost fully utilised being
either coupled to compound V to form compound VI
or hydrolysed to compound III. The total yield of
compound VI was 52% by HPLC. Preparative
HPLC yielded 270 mg of pure compound with RAt :
7.4 min; 1H NMR: N (DMSO-d6, ppm), 1.1^1.4
(12H, b, alanine(CH3), Boc(CH3)3), 1.4^1.9 (18H,
brs, L, Q, N CH2), 2.97 (6H, brs, O-CH2), 3.53 (6H,
d, Tris(CH2), J = 4 Hz), 3.75^4.43 (4H, brs, K-CH),
3.89 (3H, t, OH), 5.08 (6H, s, Ar-CH2), 6.8 (1H, d,
K-urethane NH, J = 7.4 Hz), 7.19 (3H, t, O-urethane
NH), 7.41 (15H, m, Ar(H)), 7.80 (1H, d, amide NH,
J = 8 Hz), 8.15 (1H, d, amide NH, J = 8 Hz), 8.35
(1H,. d, amide NH, J = 8 Hz).
2.2.7. N-{K-Boc [(O-Cbz) Lysyl]3-alanyl}Tris(O, OP,
OQ-mono, di- and tri-hexadecanoyl-
hydroxymethyl)aminomethane [Boc(K-Cbz)3-
AT(P)n, n = 1, 2, 3]; compounds VII-a,b,c
Compound VI (173 mg, 0.160 mmol) was dis-
solved in 3 ml DCM and 1 ml DMF. Palmitic acid
(89.6 mg, 0.35 mmol) and a catalytic amount of
DMAP were added to the reaction mixture. DCCD
(72 mg, 0.35 mmol) dissolved in 2 ml DCM was
added dropwise into the reaction mixture and stirred
at room temperature overnight. The reaction pro-
duced a mixture of mono-, di- and tri-palmitoyl rep-
resenting 17%, 40% and 43% of the ¢nal product as
determined by HPLC (System B). The solvents were
evaporated to dryness and the residue redissolved in
DCM. DCU was removed by ¢ltration and the ¢l-
trate washed with sodium bicarbonate (5%) and
water. The products were separated by preparative
HPLC followed by silica chromatography (DCM/
MeOH) yielding the monopalmitoyl (17 mg, RBt :
7.63 min) dipalmitoyl (76 mg, RBt : 8.65 min), and
tripalmitoyl (63 mg, RBt : 9.29 min);
1H NMR of
the tripalmitoyl compound: N (chloroform-d,
ppm):0.8^0.95 (9H, t, 3CH3), 1.3^1.47 (84H, m,
Boc(CH3)3, palmitoyl (CH2), alanine (CH3)), 1.47^
2.0 (18H, brs, L, Q, N CH2), 1.83 (6H, t, L-CH2),
2.28 (6H, t, K-CH2), 3.09 (6H, brs, O-CH2), 3.97
(2H, m, K-CH), 4.29 (1H, m, K-CH), 4.35 (6H, s,
Tris(CH2)), 4.47 (1H, t, KCH), 5.04 (6H, s, Ar-
CH2), 5.56 (1H, d, amide NH, J = 7 Hz), 5.7 (1H,
d, amide NH, J = 7.5 Hz), 5.78 (1H, d, amide NH,
J = 7.5 Hz), 6.92 (1H, d, K-urethane NH, J = 7.4 Hz),
7.19 (3H, t, O-urethane NH), 7.35 (15H, m, Ar(H)).
2.2.8. [(Lysyl)3-alanyl] Tris(O, OP, OQ-mono-,
di- and tri-hexadecanoyl-
hydroxymethyl)aminomethane [K3AT(P)n,
n = 1, 2, 3); compound VIII-a,b,c
Compound VII-c with n = 3 (45 mg) was dissolved
in DCM (2 ml) and cooled to 0‡C. TFA (2 ml) was
added to remove the Boc group at 0‡C for 10 min
and room temperature for 30 min. The solvent and
the excess TFA were removed thoroughly by re-
peated co-evaporation with diethylether and precipi-
tated from diethylether. Removal of the Boc protect-
ing group was con¢rmed by 1H NMR spectroscopy.
The precipitate was then dissolved in a mixed solu-
tion of DCM/methanol (50:50, 4 ml) and hydrogen-
ated for 2 h at 40 psi in a Parr Hydrogenator using
10% palladium/carbon to remove the Cbz groups.
The removal of the Cbz groups was con¢rmed by
1H NMR spectroscopy (by disappearance of chem-
ical shifts at 5.04 and 7.35 ppm).
Compounds VII-a and VII-b were deprotected by
the same method as described above. Finally the
compounds were freeze dried from TBA and stored
at 4‡C.
For transfection, freeze dried compounds were dis-
solved to 20 mM in ethanol and then diluted to 10
mM with sterile water. Working stocks (2 mM), pre-
pared by further dilution of the 10 mM stock in
sterile water, were stored at 4‡C.
2.3. Plasmids
pPGKlacZNLS [10], pCIGAL and pSVGAL [11]
are all mammalian expression vectors carrying the
gene cassette encoding L-galactosidase production.
The promoters used were mouse PGK, CMV imme-
diate early and SV40 early, respectively. In addition,
the PGK plasmid contains an SV40 nuclear localisa-
tion signal which directs the LacZ protein to the
nucleus. pCIGal was engineered on the vector back-
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bone pCI (Promega) as follows. The lacZ fusion gene
introduced into the pCI vector was assembled by
ligating the 1.4 kb HindIII-EcoRV 5P terminal frag-
ment of the lacZ gene from pSVGal to the 1.96 kb
EcoRV-BamHI 3P terminal fragment of the lacZ gene
from pMC1817 [12] in a 3-way ligation with HindIII-
BamHI cut Bluescript SK (Clontech) to produce
pBstlacZ. The entire lacZ gene from pBstlacZ was
then released as a 3.3 kb XhoI-XbaI fragment and
ligated to XhoI-XbaI cut pCI. The resultant plasmid
pCIGal carried the lacZ gene under the control of
the CMV immediate early promoter. As with
pSVGal, the reporter gene in the pCIGal expression
plasmid encodes a fusion protein containing 41 N-
terminal amino acids from the Escherichia coli xan-
thine guanine phosphoribosyl transferase (XGPRT)
enzyme, 29 N-terminal amino acids from the E. coli
tryptophanyl tRNA synthetase enzyme and the C-
terminal catalytic fragment from the E. coli L-galac-
tosidase enzyme [13].
2.4. Cell culture
Chinese hamster ovary (CHO) cells were cultured in
minimal essential medium with Earle’s salts (EMEM)
with 10% foetal calf serum (FCS) at 37‡C and 5% CO2.
Mouse 3T3 cells were grown similarly but in Dulbec-
co’s modi¢ed Eagle’s medium with 10% FCS.
2.5. Transfection and assay
Cells were seeded in an 8U9 array in 96-well mi-
crotitre trays at 1U104/well (CHO) or 2U104/well
(3T3) and allowed to adhere overnight.
In CHO cells, pPGKlacZNLS and Bluescribe
(Clontech) were used at a 1:3 ratio. Bluescribe was
used as a non-coding DNA to make up the required
plasmid levels where expression from transfected
cells was otherwise too high to give a linear read-
out in the L-galactosidase assay. In 3T3 cells, in or-
der to maximise expression of the transgene in this
lower expressing cell line, two plasmids pCIGAL and
pSVGAL were used, mixed at a 1:1 ratio.
Transfection was carried out essentially as de-
scribed by Felgner et al. [14]. Brie£y, in separate
polystyrene dilution plates, plasmid encoding L-gal-
actosidase was doubly diluted down from 2 Wg/well
(60.6 WM nucleotide in 100 Wl ¢nal complex volume),
and test transfection reagent was separately diluted
across eight wells of the plate to give either 168 WM
or 84 WM highest concentration (in 100 Wl ¢nal com-
plex volume) in serum free medium, with column 9
left free of lipid to provide a DNA-alone control.
DNA dilutions were transferred across into the
transfection reagent dilutions using a multichannel
pipette. After 10 min at room temperature, 100 Wl
of the mix was transferred into the wells of plates
of cells washed free of serum immediately prior to
transfer. After 3^6 h of incubation (generally 4 h) an
equal volume (100 Wl) of full medium (10% FCS) was
added to each well and allowed to incubate overnight
under standard conditions. In experiments compar-
ing di¡erent cells types, medium with 20% FCS was
added to bring the ¢nal concentration of FCS to 10%
for overnight incubation. Medium was exchanged for
fresh full medium and allowed to further incubate
until 48 h post transfection.
Cell viability was determined using the dye MTS
(Promega) according to the manufacturer’s instruc-
tions. The colour was allowed to develop until an
OD492=650V1. After reading the colour change at
492/650 nm, the cells were washed with PBS and
frozen at 370‡C in lysis bu¡er (1 M Tris pH 8,
0.1% Triton X-100) for subsequent L-galactosidase
assay of the lysate as described [14] using the
CPRG substrate (Boehringer Mannheim). An E.
coli L-galactosidase standard, at 1500 units/ml (No.
105031 Boehringer Mannheim) was used for conver-
sion of absorbance data to L-galactosidase units.
2.6. Analysis of data
The ‘peak’ level of transfection is de¢ned as the L-
galactosidase activity observed in that well of the
8U8 array displaying the highest levels of reporter
gene expression. The ‘summed’ data are calculated
by summing the L-galactosidase activity observed in
each well of the 8U8 array.
3. Results
3.1. Generation of three test compounds from one
synthesis
The synthesis of K3AT(P)n, n = 1, 2, 3, included
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Fig. 1. Synthesis pathway of K3AT(P)n.
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¢ve stages as shown in Fig. 1. The ¢rst and second
stages involved preparation of Boc(K-Cbz)3 and the
coupling of alanine to Tris (AT). The synthesis of
Boc(K-Cbz)3 was carried out by classical solution
methods [15]. Cbz-Ala-Tris was prepared as de-
scribed by Whittaker et al. [9] with some modi¢ca-
tion in the puri¢cation process. The third stage in-
volved activating the C-terminal carboxyl group of
the Boc(K-Cbz)3, coupling to AT and puri¢cation of
the product by preparative HPLC. The fourth stage
of the preparation included conjugation of the pal-
mitic acid to the Boc(K-Cbz)3 AT. By adding di¡er-
Fig. 2. Structures of K3AT(P)n. X, charged peptide domain; Y, amino acid spacer domain, linked through Tris to R1^R3 fatty acyl
derivative domain. Displayed from top: a, K3ATP1 ; b, K3ATP2 ; c, K3ATP3. Roman numerals refer to positions in synthesis pathway
(see Fig. 1).
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ent ratios of the palmitic acid and the coupling re-
agent (DCCD) di¡erent populations of the three
conjugates BOC(K-Cbz)3 AT(P)n, n = 1, 2, 3, were
generated. The three conjugates were then separated
on a preparative HPLC (C18 column) followed by
silica-gel chromatography to obtain high purity con-
jugates. In the last stage each conjugate was depro-
tected from Boc and Cbz groups. The purity of the
intermediates and the ¢nal products were all checked
by TLC, HPLC, and 1H NMR.
Each of these molecules was characterised by the
presence of four positive charges at the hydrophilic
end, and palmitoyl (n = 1^3) at the hydrophobic end.
The structures for these molecules are shown in Fig.
2. In this ¢gure the three di¡erent domains which can
be readily varied are designated ‘X’ (cationic do-
Fig. 3. Transfection of CHO cells. Three-dimensional histogram representations of 96-well transfection plates of (A) K3ATP1, (B)
K3ATP2, (C) K3ATP3 and (D) Lipofectamine, showing the di¡erent range of tolerances of DNA and lipid combinations which will
e¡ectively transfect CHO cells. These graphs display not only the di¡erent regions where the peak transfection occurs but also the
broadness of the range of e¡ective transfection combinations using di¡erent reagents. Y axis displays units of L-galactosidase, X axis
the range of cationic lipid concentrations in doubling dilutions from 84 WM to 0.66 WM. ‘DNA’ is the DNA-alone control. The Z
axis is the range of DNA concentrations in doubling dilutions from A = 60.6 WM to H = 0.48 WM nucleotides.
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main), ‘Y’ (spacer domain) and ‘R1 to R3’ (hydro-
phobic domain).
3.2. Demonstration of transfection
Transfection experiments were carried out using
one or more of the plasmids pPGKlacZNLS, pCI-
GAL or pSVGAL carrying a gene cassette encoding
the production of E. coli L-galactosidase. Forty-eight
hours after transfection, the cytotoxicity of the trans-
fection complexes was measured using the MTS as-
say, then transfection e⁄ciency was measured by as-
saying lysates of the same cells for L-galactosidase as
described above. Transfection was compared to that
achieved with the commercial agents Lipofectamine
or DMRIE-C (Life Technologies).
Fig. 3 shows the dramatic e¡ect on transfection in
CHO cells of changing the number of R groups in
the hydrophobic domain of the molecule. Holding
the rest of the molecule constant with three lysine
(K3) moieties, and an alanine spacer, the number
of palmitoyl molecules was varied from one to three.
The e¡ect of this variation on transfection was that
although the K3ATP1ÿ3 molecules all display some
level of transfection of CHO cells above naked
DNA, conjugates carrying two or three palmitoyl
groups show peak transfection activities 4 and 3 or-
ders of magnitude above this background control
respectively.
These data further demonstrated that the dipalmi-
toyl molecule not only gave the highest levels of
transfection of the three variants, but also gave a
level of transfection signi¢cantly greater than that
mediated by Lipofectamine. This was true whether
measured as the ‘peak’ level of transfection, or the
‘summed’ data as shown in Table 1.
The di¡erences between compounds can thus be
observed by more than one parameter when testing
in the 96-well plate assay. First, the maximal level of
transfection can be observed in a single well of the
8U8 matrix. This designates the optimal lipid:DNA
ratio and concentration for transfection mediated by
the lipid in that cell type. Second, the summed data
indicate how much variation from that optimal com-
bination of lipid and DNA can be tolerated and still
result in signi¢cant levels of transfection. This is il-
lustrated graphically in the 3D histograms of Fig. 3
where in the case of the P3 molecule peak transfec-
tion levels are signi¢cantly down relative to the P2
molecule and similar to Lipofectamine. However, as
shown in Table 1, the P3 molecule shows a sum sub-
stantially greater than its peak (sum/peak = 7) where-
as the P2 molecule results show relatively close sum
and peak values (sum/peak = 3.5), while Lipofect-
amine is intermediate (sum/peak = 5.4). The inference
from this is that as the sum/peak value approaches 1,
the range of useful transfection conditions becomes
increasingly narrow. Conversely as the value in-
creases, the useful range of conditions can be seen
as broadening, with the codicil that when both trans-
fection values are close to background, as in the P1
results, the value of sum/peak can be misleading.
3.3. Cytotoxicity
General cytotoxicity over the entire range of lipid/
DNA combinations was low. Cell viability measured
using the MTS assay on the same dish of cells sub-
sequently assayed for L-galactosidase gene product
indicated that cell survival averaged across the plate
was at least as high as when using Lipofectamine on
the same cells (Fig. 4A). Particularly, the dipalmitoyl
molecule showed a good level of viability of trans-
fected cells compared to Lipofectamine.
For in vitro transfections, perhaps the more rele-
vant data is the level of cytotoxicity at the speci¢c
Table 1
Transfection of CHO cells
Reagent Peak (units L-gal) S.E. Sum (units L-gal) S.E. Sum/peak
Lipofectamine 1.92U1033 0.048U1033 1.036U1032 0.07U1032 5.4
K3ATP1 1.03U1036 0.566U1036 1.519U1035 0.27U1035 14.7
K3ATP2 4.76U1033 0.710U1033 1.667U1032 0.21U1032 3.5
K3ATP3 8.32U1034 0.417U1034 5.835U1033 2.18U1033 7.0
Results shown are the mean ‘peak’ or ‘sum’ data from four separate experiments. Absolute values obtained from each separate experi-
ment were used to obtain mean data and standard error (S.E.) values.
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combination of lipid and DNA which gives the most
e¡ective transfection. These are shown in Fig. 4B
where it can be seen that at optimal transfection
conditions, all the variants are still enabling greater
than or equal to the cell viability observed when us-
ing Lipofectamine.
3.4. Other cells
Transfection activity of the K3ATP2 and K3ATP3
conjugates is not limited to CHO cells. Mouse 3T3
and CHO cells were grown over the same period and
transfected under essentially identical conditions,
with the exception that the transfection components
(lipid and DNA) were diluted in serum free DME
medium for 3T3 cells rather than the EMEM used
for CHO cells.
Fig. 4C and D show that the two cell lines dis-
played a similar pro¢le of optimal transfection with
the di¡erent test lipids and DMRIE-C, although the
actual level of transgene expression was reduced in
the 3T3 cells compared to CHO cells. Viability of the
cells remained good with all compounds in 3T3 cells,
as shown in Fig. 4E. However, while it is interesting
to observe that K3ATP2 was the most e¡ective facil-
itator of transfection of both cell types, it remains
possible that other cell lines may display a di¡erent
reagent preference. It has been reported by others
that di¡erent cell lines can display optimal transfec-
tion with di¡erent reagents [16].
3.5. Electron microscopy
Negative staining of lipid formulations demon-
strated that the Tris conjugate assembly resembled
branching stacks of discs which were relatively small
in size (15^20 nm in width) as shown in Fig. 5A. The
size estimate of a lipid bilayer made by Lasic [30] of
4 nm would indicate that these discs may in fact be
constructed of a squashed sphere of lipid bilayer,
described by Lasic as an oblate micelle. A compar-
ison with the commercial DOSPA:DOPE formula-
tion Lipofectamine in Fig. 5B shows a distinctively
di¡erent structure of large multilamellar liposomes of
larger dimensions (26^100 nm in diameter).
4. Discussion
Cationic lipids are well established as facilitators
of nucleic acid uptake in mammalian cells. Advan-
tages of using these types of molecules over viruses
for delivery lie mainly in the low toxicity of the prep-
arations (reviews [17,18]). This includes the reduced
risks associated with immunogenicity, oncogenicity
Fig. 4. Viability of transfected CHO cells. (A) Total plate i.e.
64 wells summed. (B) Viability of well displaying maximum
transgene expression. In both A and B levels were referred to
DNA-alone controls (4 or mean of eight wells) as 100% viabil-
ity. Viability data over four separate experiments were used.
S.E. bars are shown. Peak transfection in CHO (C) and 3T3
cell lines (D). Relative transfection mediated by K3ATP2 (2),
K3ATP3 (3), DMRIE-C (D) are shown. Optimal, or ‘peak’
transfection is displayed. S.E. bars are shown. (E) Cell viability
under conditions of optimal transfection. 100% viability as in A
and B, for each cell type. S.E. bars are shown. K3ATP2 (2),
K3ATP3 (3), DMRIE-C (D).
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Fig. 5. Transmission electron micrographs of negatively stained (A) K3ATP3 and (B) Lipofectamine. Stock samples of liposomes at
2 mM were diluted 1 in 10 with ¢ltered distilled water, and mixed 1:1 with ¢ltered negative stain (ammonium molybdate 2%, pH 6.5)
and spread onto carbon-formvar coated copper/rhodium 200 mesh electron microscope grids, and examined in a Jeol JEM 100CX
electron microscope at 60 kV at original magni¢cations of (A) 33K and (B) 50K. Micrographs have been photographically enlarged
to the same ¢nal magni¢cation. Size bars: A = 90 nm; B = 60 nm.
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and viraemia resulting from chance viral recombina-
tion events.
We have discovered a generic technology which
has enabled us to make a class of cationic lipid trans-
fection compounds whose chemical composition and
mode of synthesis o¡er the ability to make altera-
tions to the chemical properties of these compounds
in a systematic fashion with relative ease. The work
described here demonstrates one biological applica-
tion of compounds utilising this unique Tris linkage
of peptides to fatty acyl derivatives [9] in their use as
transfection reagents.
The three symmetrical hydroxyl groups on the Tris
molecule provide the opportunity to produce unique
molecules without any stereoisomers. The nature of
the fatty acyl chains at these positions can be readily
varied and need not be identical. Most previously
described synthetic cationic lipid molecules used for
transfection incorporate two fatty acyl groups or a
stereol backbone. This new cationic lipid family was
designed so that the number and structure of the
hydrophobic moieties could easily be changed from
a single chain through to a maximum of three which
has provided dramatic changes in their biological
application.
The head group in the molecules reported here
consists of a trilysine peptide producing four positive
charges. Although not yet investigated, the number
of charges in the head group could be varied by
conjugating peptides carrying a di¡erent number of
lysines to the hydrophobic backbone. The ability to
readily change the number of charges in the head
group provides the opportunity to systematically cor-
relate the e¡ect of charge in these molecules on their
interaction with DNA and with the capacity to trans-
fect genes into cells.
The three di¡erent peptide-Tris fatty acyl conju-
gates K3ATP1, P2 and P3 were synthesised in a single
esteri¢cation reaction conjugating palmitic acid to
the Boc(K-Cbz)3 AT and then separated by HPLC
and silica chromatography. However, each of these
conjugates can also be prepared separately by gener-
ating the building blocks Boc(K-Cbz)3OSU and
ATP1, ATP2 or ATP3 and subsequently coupling
the polar head group to the hydrophobic group.
The latter method is preferred when one of the con-
jugates is of particular interest and for scaling up
production.
As a rule, with most transfection molecules de-
scribed in the literature or commercially available,
including Lipofectamine and DMRIE-C, transfection
is reliant heavily on the combination of the active
molecule with a neutral lipid, usually DOPE and
occasionally cholesterol [14,19^26]. These lipids are
used to support better liposome formation, and may
enhance endocytic uptake [27,28]. Also, DOPE in
particular has been shown to have a major role in
destabilising the endosomal membrane by inducing a
lamellar-hexagonal phase transition to aid in escape
of DNA into the cytosol before lysosomal degrada-
tion occurs [29,30]. A few exceptions to this rule have
been described. One by Wheeler et al., where the
change of an alcohol to an amine in LAE-DMRIE
obviated the need for a co-lipid [31] and another
where the lipospermine DOGS (Transfectam) did
not bene¢t from the addition of DOPE [32].
Unlike most cationic lipids, the transfection activ-
ity of the Tris conjugates was independent of formu-
lation with any co-lipid, but rather relied on their
own capacity to self-assemble into membranous
structures in aqueous solution as demonstrated by
K3ATP3 in Fig. 5A. This type of lipid assembly is
notably di¡erent from that of Lipofectamine (DOS-
PA:DOPE 3:1) shown in Fig. 5B. As postulated with
DOGS [32], the Tris molecules must at least partly
incorporate the function of the fusogenic co-lipids
themselves, as they do not bene¢t from their addition
(data not shown). This non-requirement of the co-
lipid removes the need for deliberate liposome for-
mulation and greatly simpli¢es the use of these com-
pounds.
The set of molecules used in this study has an ester
bond between the hydrophobic fatty acyl backbone
and the Tris linker which can be expected to have
desirable biodegradability and biocompatibility after
transfection into cells, and therefore less cytotoxicity.
In fact, cytotoxicity indications were favourable com-
pared to commercial reagents and levels of cell via-
bility at optimal levels of transfection were particu-
larly encouraging.
Although our data shown clearly show that the P2
compound conferred higher transfection levels under
optimal conditions compared to the P3 compound in
at least two cell types, the P2 compound exhibited
high e⁄ciency in a narrow lipid:DNA ratio and con-
centration range, whereas the P3 compound was
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quite e¡ective over a broad range. In the case of cell
types more refractory to transfection, or in vivo ap-
plication, this broad tolerance may be a great ad-
vantage.
The prototype Tris conjugate cationic lipids that
we have described show great promise as gene
delivery agents, with the P2 compound already show-
ing transfection activity that is highly competitive
with two leading transfection reagents, Lipofect-
amine and DMRIE-C which are in common labora-
tory use. The di¡erent results obtained with the P1,
P2 and P3 variants provide a strong indication of the
potential for changing biological characteristics by
structural variation at the modular regions of the
molecule.
Compared to viruses, cationic lipid reagents avail-
able currently are quite ine⁄cient, resulting in rela-
tively low levels of transfection. Despite such prob-
lems, su⁄cient groundwork has been undertaken to
establish the in vivo potential of cationic lipids for
gene transfer (reviewed by Scheule and Cheng [33]).
Recent work [34] also argues that almost 100% of
cells take up the delivered nucleic acid. The barrier
to successful transfection is therefore probably not
entry into the cell, which is facilitated e⁄ciently by
cationic lipids, but rather proper transport to the
nucleus and processing of the information. This in-
dicates an area for potentially increased e⁄ciency for
this type of transfection resulting from enhanced uti-
lisation of genetic material taken in to the cell,
whether this results from manipulation of the chem-
ical structure of transfection molecules such as de-
scribed here, or the addition of other material such
as fusogenic (e.g. [35]) or targeting peptides (review
[36]). The peptide nature of the hydrophilic domain
of the Tris conjugate molecules also provides an op-
portunity to incorporate such peptides with function-
al domains into the compounds for a further level of
versatility.
The Tris-linked reagents thus lend themselves to
systematic modi¢cation of the three modular regions,
namely cationic head group (‘x’), spacer (‘y’) and
hydrophobic domains (R1 to R3) (in Fig. 1), and
evaluation of the impact of those changes on trans-
fection activity would be expected to give a broad
range of transfection opportunities from which top
performers for speci¢c applications could be chosen.
Recent e¡orts in our laboratory are currently fo-
cussed on synthesising and testing further variants at
the speci¢ed variable domains.
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